Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation | |
---|---|---|
D000073296 | Noncommunicable Diseases NIH | 0.71 |
D002908 | Chronic Disease NIH | 0.26 |
D007249 | Inflammation NIH | 0.17 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
This study is comprised of two discrete Parts. Part A is a 3-period cross over evaluating relative bioavailability. Part B is a 2-period cross over evaluating bioequivalence. There will be a minimum of a 7-day washout period between treatment periods. Participants will participate in Part A or Part B, but not both. Approximately 200 participants will be included in the study.
Description: Blood samples will be collected to measure AUC(0-t) at indicated time-points.
Measure: Part A and Part B: Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Time of Last Quantifiable Concentration (AUC[0-t]) for daprodustat Time: Pre-dose and at 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose in each Period (Each period is 24 hours)Description: Blood samples will be collected to measure Cmax at indicated time-points.
Measure: Part A and Part B: Maximum Plasma Concentration (Cmax) for daprodustat Time: Pre-dose and at 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose in each Period (Each period is 24 hours)Description: Blood samples will be collected to measure AUC(0-inf) at indicated time-points.
Measure: Part A and Part B: AUC From Time Zero to Infinity (AUC[0-inf]) for daprodustat Time: Pre-dose and at 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose in each Period (Each period is 24 hours)Description: Blood samples will be collected to measure Tmax at indicated time-points.
Measure: Part A and Part B: Time of occurrence of Cmax (Tmax) for daprodustat Time: Pre-dose and at 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose in each Period (Each period is 24 hours)Description: Blood samples will be collected to measure T1/2 at indicated time-points.
Measure: Part A and Part B: Terminal Elimination Half-life (T1/2) for daprodustat Time: Pre-dose and at 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose in each Period (Each period is 24 hours)Description: Blood samples will be collected to measure CL/F at indicated time-points.
Measure: Part A and Part B: Oral clearance (CL/F) for daprodustat Time: Pre-dose and at 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose in each Period (Each period is 24 hours)Description: Blood samples will be collected to measure V/F at indicated time-points.
Measure: Part A and Part B: Apparent Volume of Distribution (V/F) for daprodustat Time: Pre-dose and at 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose in each Period (Each period is 24 hours)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports